Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Cash & Current Investments: 2010-2019

Historic Cash & Current Investments for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Mar 2019 value amounting to $43.4 million.

  • EyePoint Pharmaceuticals' Cash & Current Investments rose 165.38% to $43.4 million in Q1 2019 from the same period last year, while for Mar 2019 it was $183.2 million, marking a year-over-year increase of 216.08%. This contributed to the annual value of $38.8 million for FY2018, which is 129.47% up from last year.
  • Latest data reveals that EyePoint Pharmaceuticals reported Cash & Current Investments of $43.4 million as of Q1 2019, which was down 4.16% from $45.3 million recorded in Q4 2018.
  • Over the past 5 years, EyePoint Pharmaceuticals' Cash & Current Investments peaked at $55.8 million during Q3 2018, and registered a low of $11.8 million during Q3 2017.
  • Its 3-year average for Cash & Current Investments is $28.5 million, with a median of $16.9 million in 2017.
  • In the last 5 years, EyePoint Pharmaceuticals' Cash & Current Investments crashed by 53.81% in 2017 and then surged by 371.26% in 2018.
  • EyePoint Pharmaceuticals' Cash & Current Investments (Quarterly) stood at $21.1 million in 2015, then dropped by 16.87% to $17.5 million in 2016, then fell by 26.56% to $12.9 million in 2017, then surged by 251.51% to $45.3 million in 2018, then skyrocketed by 165.38% to $43.4 million in 2019.
  • Its Cash & Current Investments was $43.4 million in Q1 2019, compared to $45.3 million in Q4 2018 and $55.8 million in Q3 2018.